Skip to main content

Advertisement

SpringerLink
Log in

Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

  • Preclinical Study
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The aim of this study is to evaluate the impact of CYP2D6 genotyping in predicting disease-free survival and toxicity in breast cancer patients treated with adjuvant tamoxifen. DNA from 91 patients was genotyped using the AmpliChip CYP450 GeneChip®, Roche that facilitates the classification of individuals by testing 27 alleles. When patients were grouped into group 1 (*4/*4, *4/*41, *1/*5 and *2/*5) and group 2 (the remaining genotypes), a significant difference in disease-free survival (DFS) was observed between groups (P = 0.016). The mean DFS in group 1 was 95 months in contrast with 119 months in group 2. No significant relationship was found between the CYP2D6 genotype classification and severe, mild or no toxicity (P = 0.2). Nevertheless, severe, and mild toxicity was more frequent among poor metabolizer patients than in patients with a normal metabolizer pattern (18.8 and 43.8% vs. 10.7 and 36%, respectively). In breast cancer, patients treated with adjuvant tamoxifen, non-functional and severely impaired CYP2D6 variants are associated with a worse DFS and with a higher frequency of severe and mild toxicities. Larger studies of the CYP2D6 genotype-clinical outcomes association are needed to complement initial results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609–1618. doi:10.1056/NEJM199811263392207

    Article  CAS  PubMed  Google Scholar 

  2. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0

    Article  Google Scholar 

  3. Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758–1764

    CAS  PubMed  Google Scholar 

  4. Sachse C, Brockmöller J, Bauer S et al (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–295

    CAS  PubMed  Google Scholar 

  5. Kubota T, Yamaura Y, Ohkawa N et al (2000) Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br J Clin Pharmacol 50:31–34. doi:10.1046/j.1365-2125.2000.00209.x

    Article  CAS  PubMed  Google Scholar 

  6. Griese EU, Asante-Poku S, Ofori-Adjei D et al (1999) Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 9:715–723. doi:10.1097/00008571-199912000-00006

    Article  CAS  PubMed  Google Scholar 

  7. Menoyo A, del Rio E, Baiget M (2006) Characterization of variant alleles of cytochrome CYP2D6 in a Spanish population. Cell Biochem Funct 24:381–385. doi:10.1002/cbf.1258

    Article  CAS  PubMed  Google Scholar 

  8. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee (www.cypalleles.ki.se)

  9. Miller SA, Dykes DD, Polesky H (1989) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215. doi:10.1093/nar/16.3.1215

    Article  Google Scholar 

  10. Raimundo S, Toscano C, Klein K et al (2004) A novel intronic mutation, 2988G > A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects. Clin Pharmacol Ther 76:128–138. doi:10.1016/j.clpt.2004.04.009

    Article  CAS  PubMed  Google Scholar 

  11. Nowell SA, Ahn J, Rae JM et al (2005) Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 91:249–258. doi:10.1007/s10549-004-7751-x

    Article  CAS  PubMed  Google Scholar 

  12. Wegman P, Vainikka L, Stal O et al (2005) Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 7:R284–R290. doi:10.1186/bcr993

    Article  CAS  PubMed  Google Scholar 

  13. Goetz MP, Rae JM, Suman VJ et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312–9318. doi:10.1200/JCO.2005.03.3266

    Article  CAS  PubMed  Google Scholar 

  14. Goetz MP, Knox SK, Suman VJ et al (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101:113–121. doi:10.1007/s10549-006-9428-0

    Article  CAS  PubMed  Google Scholar 

  15. Schroth W, Antoniadou L, Fritz P et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187–5193. doi:10.1200/JCO.2007.12.2705

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servicio de Oncología Médica, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain

    T. Ramón y Cajal, C. Alonso & A. Barnadas

  2. Servicio de Hematología, Fundació Althaia, Manresa, Barcelona, Spain

    A. Altés

  3. Servicio de Genética, Hospital de la Santa Creu i Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain

    L. Paré, E. del Rio & M. Baiget

Authors
  1. T. Ramón y Cajal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Altés
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Paré
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. del Rio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. Barnadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Baiget
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Baiget.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramón y Cajal, T., Altés, A., Paré, L. et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 119, 33–38 (2010). https://doi.org/10.1007/s10549-009-0328-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-009-0328-y

Keywords

Search

Navigation